Steroid Eye Drops: Uses, Side Effects, and Alternatives

Steroid eye drops are prescription anti-inflammatory medications that suppress immune activity on the surface and inside the eye, and they remain the most widely used treatment for a broad range of inflammatory eye conditions. Corticosteroids work against inflammation, swelling, and abnormal blood vessel growth in ocular tissue, which is why they show up in treatment plans for everything from post-surgical recovery to uveitis flare-ups.¹ They are remarkably effective, but that effectiveness comes with real risks that make unsupervised use genuinely dangerous.

How They Work

Steroid eye drops deliver a corticosteroid directly to the eye’s surface, where the drug penetrates the cornea and reaches the tissues behind it. Conditions affecting the front of the eye, like allergic conjunctivitis, anterior uveitis, or corneal inflammation after surgery, are well suited to topical drops because the drug can reach the target tissue without traveling through the bloodstream. Conditions farther back in the eye, such as macular edema or posterior uveitis, generally need injections around or inside the eye, or sometimes oral steroids, because a topical drop simply doesn’t penetrate deeply enough.²

Once a steroid molecule gets inside the eye, it binds to glucocorticoid receptors on cells involved in the inflammatory response. This binding turns down the production of chemical signals that recruit immune cells and cause swelling. The result is a rapid decrease in redness, pain, and tissue damage. For someone recovering from cataract surgery or dealing with an autoimmune flare inside the eye, that suppression of inflammation can be the difference between a smooth recovery and serious complications like scarring or vision loss.

What Conditions Are Treated with Steroid Eye Drops

The list is long. Steroid drops are prescribed for anterior uveitis (inflammation of the colored part of the eye and surrounding structures), severe allergic eye disease, scleritis, and episcleritis. They are a standard part of post-operative care after cataract surgery, corneal transplants, and glaucoma surgery. Some forms of dry eye disease that involve significant inflammation also benefit from short courses of topical steroids.

After cataract surgery in particular, steroid drops are used for weeks to control the inflammation triggered by the procedure itself. This is by far the most common scenario in which a patient encounters these medications. Millions of cataract surgeries are performed each year worldwide, and virtually all of them include a steroid drop in the post-operative regimen.

Common Types and How They Differ in Potency

Not all steroid eye drops are created equal. Prednisolone acetate and dexamethasone are the heavy hitters, with strong anti-inflammatory action and correspondingly higher risk of side effects like elevated eye pressure. Fluorometholone is less potent and penetrates less deeply into the eye, making it a common choice for surface-level conditions where a lighter touch is appropriate. Then there is a category often called “soft” steroids, of which loteprednol etabonate is the best known.

Loteprednol was designed to be metabolized quickly once it enters the eye, reducing the time it spends interacting with tissues that can be harmed by prolonged steroid exposure. In a head-to-head trial against prednisolone acetate after cataract surgery, loteprednol controlled inflammation equally well over a three-week follow-up, but with less fluctuation in eye pressure.³ A more recent systematic review and meta-analysis comparing standard steroids to soft steroids after cataract surgery reached a similar conclusion: for the average patient, both groups produced comparable effects on inflammation and post-operative eye pressure.⁴ That finding has made soft steroids increasingly popular when the clinical situation doesn’t demand maximum potency.

The Pressure Problem

The most talked-about risk of steroid eye drops is a rise in intraocular pressure, the fluid pressure inside the eye. Left unchecked, elevated pressure can damage the optic nerve and lead to steroid-induced glaucoma, a form of the disease that is entirely avoidable if caught in time. The connection between systemic steroids and elevated eye pressure was first reported back in 1950, and it has been studied extensively since.⁵

Not everyone is equally susceptible. A systematic review of the evidence found that the risk of pressure elevation increases with prolonged use, higher dosing frequency, younger age, and the use of more potent steroids with greater penetration into the eye.⁶ Children appear to be at higher risk than adults, and people with a personal or family history of glaucoma are more vulnerable. The tricky part is that steroid-induced pressure rises typically cause no symptoms. You feel fine. Your vision stays clear, at least until significant optic nerve damage has already occurred. This is why eye doctors check your pressure regularly whenever you’re on steroid drops for more than a short course.

Monitoring protocols have become fairly sophisticated. For intravitreal steroid implants, European consensus guidance uses a tiered system: patients whose baseline pressure is below 22 mmHg and who have no history of pressure events are classified as low risk if their first post-implant check stays below 22, medium risk if it sits between 22 and 25 with a rise under 10 mmHg from baseline, and high risk if it exceeds 25 or rises by 10 or more. Patients with higher baseline pressures or prior pressure events skip the low-risk category entirely and are monitored more frequently from the start.⁷ These thresholds give a sense of how seriously clinicians take the pressure risk, even though most patients on topical drops face a less intensive version of this monitoring.

Cataracts from Steroid Drops

The other well-known side effect is the formation of a specific type of cataract called a posterior subcapsular cataract. These develop at the back surface of the lens, right in the optical path, so even a small opacity can be noticeable. They tend to form with prolonged use rather than short courses.

The mechanism has been studied in laboratory and animal models for decades. Research on rat lenses showed that glucocorticoid steroids, but not other types of steroids, depleted a protective molecule called glutathione in the lens. This depletion is an early step that appears linked to the eventual clouding of the lens.⁸ Separate work has identified that steroid-induced cataracts involve aberrant migration of lens cells to a location where they don’t normally appear, which is what produces the distinctive pattern seen under a slit lamp. Only steroids with glucocorticoid activity cause this kind of cataract, pointing to glucocorticoid receptor activation as a key trigger.⁹

For someone using steroid drops for a few weeks after surgery, the cataract risk is minimal. For someone on daily drops for months or years because of chronic uveitis, it becomes a real concern that needs to be weighed against the consequences of uncontrolled inflammation.

Infection Risk and When Steroids Become Dangerous

Steroids suppress the immune response, which is the whole point when the immune system is causing harmful inflammation. But that same suppression can let infections take hold or worsen. Using steroid drops on an active corneal infection without adequate antimicrobial coverage is one of the most dangerous mistakes in eye care.

The risk varies by the type of infection. For bacterial keratitis and herpes simplex keratitis, effective antimicrobials exist, so adding steroids to reduce scarring can be done safely under supervision. Fungal and amoebic infections are a different story. The antimicrobial drugs available for these organisms are less effective, meaning steroids can allow the pathogen to multiply and drive the infection deeper into the cornea.¹⁰ This is why eye doctors are extremely cautious about prescribing steroid drops for a red eye before they’ve ruled out infection, and why using leftover steroid drops from a previous prescription without a doctor’s guidance can go badly wrong.

Steroid drops can also delay the healing of corneal wounds.¹¹ In animal studies, prednisolone reduced corneal wound strength by about 20% and significantly decreased collagen formation in healing scars.¹² For this reason, doctors carefully time steroid use around corneal injuries, balancing the benefit of reduced inflammation against the cost of slower healing.

Why You Cannot Just Stop Taking Them

Abruptly stopping steroid eye drops can trigger rebound inflammation, where the original swelling and redness come roaring back, sometimes worse than the initial episode. This has been well documented across clinical settings.¹³ A recent randomized clinical trial found that rebound effects were particularly prominent when steroid treatment was discontinued after only 10 days, underscoring the importance of gradual tapering schedules.¹⁴

A typical taper after cataract surgery might start with drops four times a day during the first week, then step down to three times, then twice, then once, over a period of about four to six weeks total. The exact schedule varies by surgeon and by how the eye is responding. The key point for patients is this: even if your eye feels perfectly fine after a week, do not skip the remaining doses or stop early without talking to your doctor. The rebound can set you back and may require restarting treatment.

Do Steroid Eye Drops Affect the Rest of Your Body

People sometimes worry about the systemic side effects associated with oral steroids, like weight gain, blood sugar spikes, and bone loss. With topical eye drops, systemic absorption is generally low. A study measuring dexamethasone concentrations after topical application found mean blood levels of just 0.7 nanograms per milliliter, compared with 30.5 nanograms per milliliter in the fluid at the front of the eye.¹⁵ That is a roughly 40-fold difference, and the blood levels are far below what would be expected to cause whole-body effects.

That said, the drug does get into the bloodstream. In rare situations, particularly with very frequent dosing in children or prolonged use, there have been case reports of adrenal suppression. These are unusual enough that most ophthalmologists don’t consider it a routine concern, but it’s another reason why steroid drops should be used at the lowest effective dose for the shortest necessary time.

NSAID Eye Drops as Alternatives

Nonsteroidal anti-inflammatory drugs (NSAIDs) are available as eye drops too, and they offer an important advantage: they do not raise eye pressure or cause cataracts.¹⁶ Common NSAID eye drops include ketorolac, nepafenac, and bromfenac. They are widely used after cataract surgery, either alone or alongside a steroid.

A comparative study found that NSAIDs controlled pain and redness better than steroids in the early days after cataract surgery, while prednisolone was somewhat better at controlling intraocular inflammation overall.¹⁷ An American Academy of Ophthalmology report noted that there was no evidence that benefits from NSAID therapy could not be similarly obtained with equivalent dosing of a steroid, suggesting significant overlap between the two classes.¹⁸

NSAIDs are not without their own issues, though. Mild burning and stinging are common, and in rare cases they can cause a serious complication called corneal melt, particularly in patients with existing corneal disease. So while NSAIDs are a useful alternative for patients who are steroid responders (people whose pressure rises significantly with any steroid), they are not a universal replacement.

The Self-Medication Problem

In many countries, steroid eye drops are available over the counter or without a meaningful prescription gatekeeping process. This creates a serious public health issue. A study of patients who self-medicated with steroid drops found that roughly 28% developed complications, including eye infections, glaucoma, and cataracts.¹⁹ The most insidious of these is glaucoma, because patients using potent steroids like dexamethasone for minor irritation often have no idea their pressure is climbing until the optic nerve is already damaged. By the time they seek care, the damage can be irreversible.²⁰

The pattern is depressingly consistent: someone gets a red, irritated eye, uses a steroid drop that worked for them before (or was recommended by a pharmacist or friend), feels better quickly, and keeps using it for weeks or months. Without pressure checks, they have no way of knowing that something is going wrong until vision loss becomes obvious. This is one of the clearest cases in ophthalmology where the medication’s effectiveness works against the patient. The drops feel like they’re doing exactly what they should, while quietly causing damage that cannot be undone.

Who Is at Higher Risk for Side Effects

Children are more susceptible to steroid-induced pressure elevation than adults.²¹ This is relevant because children with conditions like vernal keratoconjunctivitis (a severe allergic eye disease common in warm climates) sometimes need repeated or prolonged courses of steroid drops. Pediatric ophthalmologists monitor these patients closely, and they tend to reach for lower-potency options or NSAID alternatives whenever possible.

People with existing glaucoma or a family history of glaucoma are another high-risk group. Studies have consistently shown that first-degree relatives of people who develop steroid-induced pressure elevation are more likely to experience it themselves, suggesting a genetic component.²² Myopic patients (those who are nearsighted) and people with type 1 diabetes also appear to be at somewhat greater risk, though the data are thinner for these groups.

Genetics of Steroid Response

Researchers have long suspected that the tendency to develop elevated eye pressure from steroids is heavily influenced by genetics. Family studies support this, but identifying the specific genes involved has proven difficult. A 2019 review of the field described it as “positioned for discovery” but noted that reproducible genetic findings had not yet emerged.²³

Progress has been made since. Whole-genome sequencing of patients who developed elevated pressure after steroid injections identified variants in genes involved in cell structure and tissue remodeling, including genes called CRPPA, PLOD1, and ARHGAP1.²⁴ A pharmacogenomic study identified 44 genetic variants of genome-wide significance across 26 risk locations in the genome. Interestingly, most of these variants were rare or low-frequency in the general population, likely detectable because each one has a large individual effect on pressure response.²⁵

The practical payoff of this genetic research is still in the future. Someday, a simple test before starting steroid drops could flag patients who are genetically prone to dangerous pressure spikes. For now, the best approach remains close monitoring with pressure checks, particularly in people with known risk factors.

Sustained-Release Implants and Newer Delivery Methods

One of the ongoing challenges with steroid eye drops is adherence. Patients forget doses, contaminate the bottle tip, struggle with the physical act of putting drops in, or stop the taper early. These problems have driven interest in drug delivery systems that bypass the drop bottle entirely.

Sustained-release corticosteroid implants are already in clinical use for conditions affecting the back of the eye. Three devices have become established: Ozurdex, which releases dexamethasone over weeks to months; and two fluocinolone acetonide implants, Retisert and Iluvien, which can deliver drug for months to years.²⁶ These implants are primarily used for diabetic macular edema and non-infectious posterior uveitis, conditions where the inflammation is deep in the eye and needs long-term control.

For cataract surgery, a newer approach involves placing a sustained-release steroid deposit at the time of surgery, eliminating the need for weeks of post-operative drops. A study comparing a single subconjunctival injection of betamethasone to a standard course of dexamethasone drops found comparable results for both inflammation control and prevention of macular edema, suggesting the depot approach is a viable alternative.²⁷ The appeal for patients is obvious: one injection instead of weeks of remembering to use drops four times a day. These sustained-release options also offer improved compliance and greater patient convenience, which matters when the alternative depends entirely on the patient’s ability to follow a complicated tapering schedule at home.²⁸

The pressure risk does not disappear with implants. In fact, because the steroid is continuously released, some patients experience prolonged elevation that requires pressure-lowering drops or even surgical intervention. The same monitoring principles apply, just over a longer timeframe.